The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

Inclusion Criteria: 1. 18 years ≤ age ≤ 80 years; 2. Histologically or cytologically confirmed NSCLC; 3. Resectable stage IB, II, IIIA, or IIIB (N2) NSCLC according to the staging criteria of the American Joint Committee on Cancer (8th edition); 4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 at baseline; 5. With measurable or evaluable diseases according to the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) at baseline; 6. Achieving pathological complete response (pCR) after three cycles of neoadjuvant chemoimmunotherapy, which was assessed by independent pathological examination of surgical specimens; 7. With or without adjuvant immunotherapy postoperatively; 8. Signed and dated written informed consent provided by the patient prior to admission to the study. Exclusion Criteria: 1. EGFR or ALK aberrations positive; 2. With primary/secondary immunodeficiency diseases or symptomatic interstitial lung diseases; 3. With a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone or equivalents) or other immunosuppressive medications within 14 days of study drug administration; 4. With other active malignant tumors currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drugs; 5. Receipt of other investigational drugs during the observation period; 6. Unable to follow the procedures required in the protocol due to any medical, mental or psychological conditions.